Therapy for acute/subacute musculoskeletal pain: results of the ATUSA (Analgesic Treatment Using a Systemic Algorithm) observational study


Cite item

Full Text

Abstract

Aim. To evaluate the efficiency of therapy for acute/subacute musculoskeletal pain (MSP) by applying an individualized pathogenetic approach (an algorithm) elaborated on the basis of Russian experts’ recommendations. Subjects and methods. A total of 262 physicians treating patients with rheumatic diseases participated in the ATUSA (Analgesic Treatment Using a Systemic Algorithm) program. The study enrolled 3,304 patients (54.3% women, 45.7% men; mean age, 48.6±14.3 years) with osteoarthritis, nonspecific back pain (NBP), and rheumatic diseases of periarticular soft tissues, who had experienced MSP. Treatment was performed in accordance with the following algorithm: the first prescribed medication was nonsteroidal anti-inflammatory drugs (NSAIDs) (aceclofenac): paracetamol and/or tramadol and a topical NSAID in case of contraindications and muscle relaxants in case of indications. The results of treatment were assessed after 7, 14, and 28 days. The treatment was corrected during each visit; the NSAID was, if necessary, changed; corticosteroids were locally injected; antidepressants or anticonvulsant drugs were used. The investigators assessed dynamic changes in pain using a 0—10 paint intensity numeric rating scale (NRS), the number of patients, in whom MSP was completely relieved, and satisfaction with treatment. Results. The first prescribed medication was oral NSAIDs in 97.5% of the patients and those in combination with a muscle relaxant in 67.6%. By visit 4, MSP decreased from 6.9±1.5 to 2.2±1.3 NRS scores. After 28 days, only 16.2% of patients continued to need analgesics. 88.4% of the patients rated treatment results as good or excellent. NSAID switching was required in 8.1% of cases; local glucocorticosteroid injections were needed in 1.9%; there was a need for the use of an antidepressant or anticonvulsant in 1.5% and for hospitalization in 0.25%. Adverse events were observed in 2.2% of patients. The efficiency of treatment (complete pain relief after 28 days) was influenced by the following factors: NRS diagnosis (OR, 2.24; 95% CI, 1.67 to 3.11), age ≥65 years (OR, 0.72; 95% CI, 0.52 to 0.98), moderate pain (NRS scores of ≤7) at the beginning of the study (OR, 2.63; 95% CI, 1.99 to 3.48), mild/moderate pain (NRS scores of <4) after 7 days of therapy (OR, 2.5; 95% CI, 1.89 to 3.33), and the use of muscle relaxants (OR, 1.77; 95% CI, 1.23 to 2.96) (p<0.05 for all comparisons). Conclusion. The comprehensive pathogenetic approach used in analgesic therapy provides an effective and relatively safe relief of MSP in most patients with NBP and osteoarthritis.

About the authors

A E Karateev

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» РАМН

Москва, Россия

L I Alekseeva

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» РАМН

Москва, Россия

A V Tsurgan

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» РАМН

Москва, Россия

N V Gontarenko

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» РАМН

Москва, Россия

References

  1. Насонов Е.Л., Насонова В.А. Фармакотерапия боли:взгляд ревматолога. Consilium medicum. 2000;2(12):7-14.
  2. Murray CJ, Barber RM, Foreman KJ, Abbasoglu Ozgoren A, Abera SF, Aboyans V, Abraham JP, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet. 2015;386(10009):2145-2191. https://doi.org/10.1016/s0140-6736(15)61340-x
  3. Каратеев А.Е. Болезни костно-мышечной системы в практике 2102 врачей разных специальностей:структура патологии и мнение специалистов об эффективности НПВП (предварительные данные эпидемиологического исследования КОРОНА-2). Consilium medicum. 2013;9:95-100.
  4. Боль (практическое руководство для врачей). Под ред. Яхно Н.Н., Кукушкина М.Л., М.: Издательство РАМН, 2012.
  5. Каратеев А.Е., Насонов Е.Л., Яхно Н.Н., Ивашкин В.Т., Чичасова Н.В., Алексеева Л.И., Карпов Ю.А., Евсеев М.А., Кукушкин М.Л., Данилов А.Б., Воробьева О.В., Амелин А.В., Новикова Д.С., Драпкина О.М., Копенкин С.С., Абузарова Г.Р. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;1:4-24.
  6. Насонов Е.Л., Яхно Н.Н., Каратеев А.Е., Алексеева Л.И., Баринов А.Н., Барулин А.Е., Давыдов О.С., Данилов А.Б., Журавлева М.В., Заводовский Б.В., Копенкин С.С., Кукушкин М.Л., Парфенов В.А., Страхов М.А., Тюрин В.П., Чичасова Н.В., Чорбинская С.А. Общие принципы лечения скелетно-мышечной боли:междисциплинарный консенсус. Научно-практическая ревматология. 2016;54(3):247-265.
  7. Blondell RD, Azadfard M, Wisniewski AM. Pharmacologic therapy for acute pain. Am Fam Physician. 2013;87(11):766-772.
  8. Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res. 2015;8:105-118. https://doi.org/10.2147/jpr.s75160
  9. Roelofs PD, Deyo RA, Koes BW, Scholten RJ, van Tulder MW. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev. 2008;(1):CD000396. https://doi.org/10.1002/14651858.cd000396.pub3
  10. Bjordal J, Klovning A, Ljunggren A, Slørdal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain:A meta-analysis of randomised placebo-controlled trials. Eur J Pain. 2007;11(2):125-138. https://doi.org/10.1016/j.ejpain.2006.02.013
  11. McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, Hawker GA, Henrotin Y, Hunter DJ, Kawaguchi H, Kwoh K, Lohmander S, Rannou F, Roos EM, Underwood M. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014;22(3):363-388. https://doi.org/10.1016/j.joca.2014.01.003
  12. Koes B.W., van Tulder M., Lin C.W., Macedo L.G., McAuley J., Maher C. An updated overview of clinical guidelines for the management of non-specific low back pain in primary care. Eur Spine J. 2010;19(12):2075-2094. https://doi.org/10.1007/s00586-010-1502-y
  13. Ревматология. Клинические рекомендации. Под ред. академика Насонова Е.Л., М.:ГЭОТАР-Медиа, 2010.
  14. Лила А.М. Применение Аэртала (ацеклофенака) в клинической практике. Российский медицинский журнал. 2009;4:291-295.
  15. Насонова В.А., Каратеев А.Е. Симптоматическая терапия боли при ревматических заболеваниях:место ацеклофенака. Современная ревматология. 2009;3:58-66.
  16. Dooley M, Spencer CM, Dunn CJ. Aceclofenac:a reappraisal of its use in the management of pain and rheumatic disease. Drugs. 2001;61(9):1351-1378. https://doi.org/10.2165/00003495-200161090-00012
  17. Lemmel E, Leeb B, De Bast J, Aslanidis S. Patient and physician satisfaction with acec-lofenac: results of the European Observational Cohort Study (experience with aceclofenac for inflammatory pain in daily practice). Aceclofenac is the treatment of choice for patients and physicians in the management of inflammatory pain. Curr Med Res Opin. 2002;18(3):146-153. https://doi.org/10.1185/030079902125000507
  18. Шарапова Е.П., Таскина Е.А., Раскина Т.А., Виноградова И.Б., Иванова О.Н., Меньшикова Л.В., Алексеева Л.И. Ацеклофенак в терапии остеоартроза. Лечащий врач. 2012;8:90-94.
  19. Каратеев А.Е., Денисов Л.Н., Маркелова Е.И., Гукасян Д.А., Демидова Н.В., Касумова К.А., Насонов Е.Л. Результаты клинического исследования АЭРОПЛАН (анализ эффективности и риска осложнений при лечении артрита ацеклофенаком и нимесулидом). Consilium Medicum. 2013;15 (2):48-53.
  20. Castellsague J, Riera-Guardia N, Calingaert B, Varas-Lorenzo C, Fourrier-Reglat A, Nicotra F, Sturkenboom M, Perez-Gutthann S. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012;35(12):1127-1146. https://doi.org/10.1007/bf03261999
  21. Paisley P, Serpell M. Controlling joint pain in older people. Practitioner. 2016;260(1789):11-15.
  22. Wong AY, Karppinen, Samartzis D. Low back pain in older adults:risk factors, management options and future directions. Scoliosis Spinal Disord. 2017;12:14. https://doi.org/10.1186/s13013-017-0121-3
  23. Nawai A, Leveille SG, Shmerling RH, van der Leeuw G, Bean JF. Pain severity and pharmacologic pain management among community-living older adults: the MOBILIZE Boston study. Aging Clin Exp Res. 2017;21. https://doi.org/10.1007/s40520-016-0700-9
  24. Larsson C, Hansson EE, Sundquist K, Jakobsson U. Chronic pain in older adults: prevalence, incidence, and risk factors. Scand J Rheumatol. 2016;25:1-9. https://doi.org/10.1080/03009742.2016.1218543
  25. Koes BW, van Tulder M, Lin CW, Lin C-WC, Macedo LG, McAuley J, Maher C. An updated overview of clinical guidelines for the management of non-specific low back pain in primary care. Eur Spine J. 2010;19(12):2075-2094. https://doi.org/10.1007/s00586-010-1502-y
  26. Maher C, Underwood M, Buchbinder R. Non-specific low back pain. Lancet. 2016 Oct 10. https://doi.org/10.1016/s0140-6736(16)30970-9
  27. Taylor N. Nonsurgical Management of Osteoarthritis Knee Pain in the Older Adult. Clin Geriatr Med. 2017;33(1):4-51. https://doi.org/10.1016/j.cger.2016.08.004
  28. Dubin A. Managing Osteoarthritis and Other Chronic Musculoskeletal Pain Disorders. Med Clin North Am. 2016;100(1):143-150. https://doi.org/10.1016/j.mcna.2015.08.008
  29. Jones MR, Ehrhardt KP, Ripoll JG, Sharma B, Padnos IW, Kaye RJ, Kaye AD. Pain in the Elderly. Curr Pain Headache Rep. 2016;20(4):23. https://doi.org/10.1007/s11916-016-0551-2
  30. Moore R, Moore O, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann Rheum Dis. 2010;69:374-379. https://doi.org/10.1136/ard.2009.107805
  31. Rundell SD, Sherman KJ, Heagerty PJ, Mock CN, Dettori NJ, Comstock BA, Avins AL, Nedeljkovic SS, Nerenz DR, Jarvik JG. Predictors of Persistent Disability and Back Pain in Older Adults with a New Episode of Care for Back Pain. Pain Med. 2017;18(6):1049-1062. https://doi.org/10.1093/pm/pnw236
  32. Farrokhi S, Chen YF, Piva SR, Fitzgerald GK, Jeong J-H, Kwoh CK. The Influence of Knee Pain Location on Symptoms, Functional Status, and Knee-related Quality of Life in Older Adults With Chronic Knee Pain: Data From the Osteoarthritis Initiative. Clin J Pain. 2016;32(6):463-470. https://doi.org/10.1097/ajp.0000000000000291
  33. Granan LP. The Ising Model Applied on Chronification of Pain. Pain Med. 2016;17(1):5-9. https://doi.org/10.1111/pme.12933
  34. Karabis A, Nikolakopoulos S, Pandhi S, Papadimitropoulou K, Nixon R, Chaves RL, Moore RA. High correlation of VAS pain scores after 2 and 6 weeks of treatment with VAS pain scores at 12 weeks in randomised controlled trials in rheumatoid arthritis and osteoarthritis: meta-analysis and implications. Arthritis Res Ther. 2016;18:73. https://doi.org/10.1186/s13075-016-0972-7
  35. Jensen MP, Wang W, Potts SL, Gould EM. The meaning of global outcome measures in pain clinical trials: more than just change in pain intensity. Clin J Pain. 201;29(4):289-295. https://doi.org/10.1097/ajp.0b013e3182527b74
  36. van Tulder MW, Touray T, Furlan AD. Solway S, Bouter LM, editors:van Tulder MW. Muscle relaxants for non-specific low back pain. Cochrane Database Syst Rev 2003;(2). https://doi.org/10.1002/14651858.cd004252
  37. Abdel Shaheed C, Maher CG, Williams KA, McLachlan AJ. Efficacy and tolerability of muscle relaxants for low back pain: Systematic review and meta-analysis. Eur J Pain. 2017;21(2):228-237. https://doi.org/10.1002/ejp.907
  38. Pratzel HG, Alken RG, Ramm S. Efficacy and tolerance of repeated doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: results of a prospective placebo-controlled double-blind trial. Pain. 1996;67(2-3):417-425. https://doi.org/10.1016/0304-3959(96)03187-9
  39. Кукушкин М.Л. Современный взгляд на механизм действия Мидокалма. Consilium medicum. 2013;2:89-94.
  40. Шарапова Е.П., Алексеева Л.И., Зайцева Е.М., Кашеварова Н.Г., Братыгина Е.А. Применение миорелаксантов в комплексной терапии остеоартроза. Consilium medicum. 2008;2:30-32.

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies